Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3607012 | 0.97 | ARG1 (0.35) | ARG1ALDH1A1FFAR3ARG2MEN1 | |
| SCHEMBL3457456 | 0.85 | ARG1 (0.36) | ARG1ALDH1A1ARG2MEN1CYP1A2 | |
| SCHEMBL18355989 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL28465870 | 0.76 | LMNA (0.48) | ARG1ALDH1A1ARG2CYP1A2CYP2D6 | |
| SCHEMBL17371358 | 0.76 | ALDH1A1 (0.32) | ALDH1A1FFAR3MEN1CYP1A2THRB | |
| SCHEMBL2590837 | 0.74 | FFAR3 (0.36) | ALDH1A1FFAR3MEN1CYP1A2THRB | |
| SCHEMBL29869191 | 0.74 | ARG1 (0.38) | ARG1ARG2 | |
| SCHEMBL12201567 | 0.74 | DGAT1 (0.34) | ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL28528880 | 0.74 | ARG1 (0.31) | ARG1 | |
| SCHEMBL30086069 | 0.72 | ALDH1A1 (0.33) | ALDH1A1FFAR3MEN1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759285-B2 | Mixture of a salt of 3-(dimethylamino)-2-(hydroxyl)-butylate and an amine compound of 3,3'-diaminopropylamine, 4-aminomethylpiperidine, or 2-aminomethylpiperidine which promotes the reaction | KOREA ELECTRIC POWER CORPORATION (KR) | 2010-07-20 | — | — | US | claimed |
| CN-101190397-A | Absorbent for separation of carbon dioxide | KOREA ELECTRIC POWER CORP (KR) | 2008-06-04 | — | — | CN | claimed |
| US-20080125314-A1 | Mixture of a salt of 3-(dimethylamino)-2-(hydroxyl)-butylate and an amine compound of 3,3'-diaminopropylamine, 4-aminomethylpiperidine, or 2-aminomethylpiperidine which promotes the reaction | KOREA ELECTRIC POWER CORPORATION (KR) | 2008-05-29 | — | — | US | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| CN-101190397-A | Absorbent for separation of carbon dioxide | KOREA ELECTRIC POWER CORP (KR) | 2008-06-04 | — | — | CN | disclosed |
| US-20080125314-A1 | Mixture of a salt of 3-(dimethylamino)-2-(hydroxyl)-butylate and an amine compound of 3,3'-diaminopropylamine, 4-aminomethylpiperidine, or 2-aminomethylpiperidine which promotes the reaction | KOREA ELECTRIC POWER CORPORATION (KR) | 2008-05-29 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | ARG1 3026/4885ALDH1A1 1175/4885FFAR3 1682/4885 |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | ARG1 2962/4885ALDH1A1 1088/4885FFAR3 2145/4885 |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | ARG1 2962/4885ALDH1A1 1088/4885FFAR3 2145/4885 |
| US-20080125314-A1 | Mixture of a salt of 3-(dimethylamino)-2-(hydroxyl)-butylate and an amine compound of 3,3'-diaminopropylamine, 4-aminomethylpiperidine, or 2-aminomethylpiperidine which promotes the reaction | SLC7A1, ALDH7A1, DDC | ARG1 326/4885ALDH1A1 106/4885FFAR3 2086/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | ARG1 1946/4885ALDH1A1 3053/4885FFAR3 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.